Welcome to Anagrammer Crossword Genius! Keep reading below to see if nbi is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on nbi.
nbi
Searching in Crosswords ...
The answer NBI has 0 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word NBI is NOT valid in any word game. (Sorry, you cannot play NBI in Scrabble, Words With Friends etc)
There are 3 letters in NBI ( B3I1N1 )
To search all scrabble anagrams of NBI, to go: NBI?
Rearrange the letters in NBI and see some winning combinations
Scrabble results that can be created with an extra letter added to NBI
Searching in Dictionaries ...
Definitions of nbi in various dictionaries:
No definitions found
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
| Nbi might be related to |
|---|
| Elagolix, sold under the brand name Orilissa, is a gonadotropin-releasing hormone antagonist (GnRH antagonist) medication which is used in the treatment of pain associated with endometriosis in women. It is also under development for the treatment of uterine fibroids in women. The medication was under investigation for the treatment of prostate cancer and enlarged prostate in men as well, but development for these conditions was discontinued. Elagolix is taken by mouth once or twice per day. It can be taken for up to 6 to 24 months, depending on the dosage.Side effects of elagolix include menopausal-like symptoms such as hot flashes, night sweats, insomnia, amenorrhea, mood changes, anxiety, and decreased bone density, among others. Elagolix is a GnRH antagonist, or an antagonist of the gonadotropin-releasing hormone receptor (GnRHR), the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH). By blocking the GnRHR, it dose-dependently suppresses the gonadal production and hence circulating levels of sex hormones such as estradiol, progesterone, and testosterone. Elagolix is a short-acting GnRH antagonist, and can be used to achieve either partial or more substantial suppression of sex hormone levels. Reduced estrogen levels in the endometrium are responsible for the efficacy of elagolix in the treatment of endometriosis.Elagolix was first described in 2008 and was approved for medical use in July 2018. It is expected to be available at pharmacies in the United States in early August 2018. Elagolix has been described as a "second-generation" GnRH modulator due to its non-peptide and small-molecule nature and its oral activity. Unlike GnRH agonists and older GnRH antagonists, which are peptides and first-generation GnRH modulators, elagolix is not a GnRH analogue as it is not structurally related to GnRH. Elagolix is the first and currently only second-generation and orally active GnRH modulator to have been introduced for medical use. It will cost about US$850 per month. |